As the world leader in antibody services, our decades of research experience converge with advanced AI to identify, engineer, and de-risk molecules for clinical readiness. We harness our expertise in in vivo antibody discovery through cutting-edge technologies to generate high-affinity antibodies with exquisite specificity and deep characterization for a phenotypically rich output. AI-enabled, multiparametric in silico workflows such as paratope binning, epitope mapping, humanization and immunogenicity assessment are infinitely scalable and accelerate discovery while maximizing the natural immune repertoire’s benefits. This fully integrated strategy sets a new standard in antibody development.